6-溴-5-氟吲哚啉-2-酮 | 893620-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 6-溴-5-氟吲哚啉-2-酮
• 中文别名: 6-溴-5-氟-1,3-二氢-吲哚-2-酮
• 英文名称: 6-Bromo-5-fluoroindolin-2-one
• 英文别名: 6-bromo-5-fluoro-1,3-dihydroindol-2-one
• CAS: 893620-44-5
• 化学式: C₈H₅BrFNO
• 分子量: 230.03
• InChiKey: YWZPDMAAXMNKIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010012747A1

  公开（公告）日：2010-02-04

  The present invention encompasses compounds of general formula (1), wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）中的化合物，其中R1至R4如权利要求书中所定义，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物。
• [EN] CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2,4-DIOXOPYRIMIDINE INHIBANT CD73
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222522A1

  公开（公告）日：2021-11-04

  The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

  本公开提供了嘧啶二酮类化合物及其药物组合物，用于治疗癌症，包括实体肿瘤。这些化合物可以单独使用或与其他抗癌药物联合使用。
• [EN] INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS INDOLIN-2-ONE OU PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014202493A1

  公开（公告）日：2014-12-24

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar is a heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O; R1 is hydrogen, lower alkyl, halogen, amino, dimethylamino, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, CH(OH)CF3, (CH2)o-lower alkoxy, cycloalkyl optionally substituted by CF3, or heterocycloalkyl optionally substituted by lower alkyl; R2 is hydrogen, lower alkyl, (CH2)o-cycloalkyl, (CH2)o-O-cycloalkyl, (CH2)o-lower alkoxy, CH2)o-lower alkoxy substituted by halogen, (CH2)o-heterocycloalkyl optionally substituted by lower alkyl, (CH2)o-S(O)2-cycloalkyl, lower alkyl substituted by one or two hydroxy, lower alkyl substituted by one or two lower alkoxy, (CH2)o-S(O)2-lower alkyl, lower alkyl substituted by halogen or CH2CH(OH)CF3; R3 is halogen or lower alkyl; X is CH or N; X1 is CH or N; n is 1 or 2; o is 0, 1, 2 or 3; m is 0, 1 or 2; and the dotted line is a bond or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof The compounds may be used for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及通式（I）中的2-氧代-2,3-二氢吲哚，其中Ar是一个杂环烃基，含有一个、两个或三个杂原子，选自N、S或O；R1是氢、低碳基、卤素、氨基、二甲胺基、氰基、被卤素取代的低碳基、被羟基取代的低碳基、CH(OH)CF3、（CH2）o-低碳醚、环烷基（可选地被CF3取代）、或杂环烷基（可选地被低碳基取代）；R2是氢、低碳基、（CH2）o-环烷基、（CH2）o-O-环烷基、（CH2）o-低碳醚、被卤素取代的（CH2）o-低碳醚、（CH2）o-杂环烷基（可选地被低碳基取代）、（CH2）o-S(O)2-环烷基、被一个或两个羟基取代的低碳基、被一个或两个低碳醚取代的低碳基、（CH2）o-S(O)2-低碳基、被卤素或CH2CH(OH)CF3取代的低碳基；R3是卤素或低碳基；X是CH或N；X1是CH或N；n是1或2；o是0、1、2或3；m是0、1或2；虚线是键或非键；以及其在药学上可接受的盐、消旋混合物、或其相应的对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗某些中枢神经系统障碍，包括精神病（阳性和阴性症状）、精神分裂症、物质滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重性抑郁症、治疗难治性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、睡眠障碍、慢性疲劳综合征、僵硬、关节炎的抗炎作用和平衡问题。
• [EN] 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] 2-OXO-2,3-DIHYDRO-INDOLES DESTINÉS AU TRAITEMENT DE TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014040969A1

  公开（公告）日：2014-03-20

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein (N1) is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; (N2) is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be on all free positions; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy or halogen; n is 1 or 2; if n is 2, R1 may be the same or not; R2/R2' are independently from each other lower alkyl, or form together with the carbon atom to which they are attached a C3-6-cycloalkyl ring; R3 is lower alkyl, C3-6-cycloalkyl, CH2-C3-6-cycloalkyl, C3-6-cycloalkyl wherein one ring-carbon atom is replaced by -O-, (CH2)3-O-C3-6-cycloalkyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, (CH2)3-S(O)2-C3-6-cycloalkyl or (CH2)2-S(O)2-lower alkyl; R4 is hydrogen, halogen or lower alkyl; m is 1 or 2; if m is 2, R4 may be the same or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

  本发明涉及一般式(I)的2-氧代-2,3-二氢吲哚，其中（N1）是苯基或杂环芳基，选择自吡啶基、嘧啶基、咪唑基、异噁唑基或吡唑基；（N2）是苯基或吡啶基，其中吡啶基中的N原子可以在所有自由位置上；R1是氢、低碳基、被卤素取代的低碳基、低烷氧基或卤素；n为1或2；若n为2，则R1可以相同也可以不同；R2/R2'彼此独立地为低碳基，或与它们连接的碳原子一起形成一个C3-6环烷基环；R3是低碳基、C3-6环烷基、CH2-C3-6环烷基、C3-6环烷基其中一个环碳原子被-O-取代、（CH2）3-O-C3-6环烷基、被羟基取代的低碳基、被卤素取代的低碳基、（CH2）3-S(O)2-C3-6环烷基或（CH2）2-S(O)2-低碳基；R4是氢、卤素或低碳基；m为1或2；若m为2，则R4可以相同也可以不同；以及其药学上可接受的盐、消旋混合物、或其对应的对映体和/或光学异构体和/或立体异构体。
• COMPOUNDS
  申请人：Treu Matthias

  公开号：US20110263565A1

  公开（公告）日：2011-10-27

  The present invention encompasses compounds of general formula (1), wherein R 1 to R 4 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物，其中R1到R4如权利要求1所定义，适用于治疗由过度或异常细胞增殖表征的疾病，并且它们的用途用于制备具有上述特性的药物。